HALO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HALO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-17), Halozyme Therapeutics's current share price is $44.73. Halozyme Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $2.78. Halozyme Therapeutics's Cyclically Adjusted PS Ratio for today is 16.09.
The historical rank and industry rank for Halozyme Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Halozyme Therapeutics's highest Cyclically Adjusted PS Ratio was 79.55. The lowest was 13.00. And the median was 26.37.
HALO's Cyclically Adjusted PS Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Halozyme Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.520. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.78 for the trailing ten years ended in Mar. 2024.
The historical data trend for Halozyme Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 18.12 | 15.82 | 15.64 | 14.24 | 14.63 |
For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Halozyme Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 44.73 | / | 2.78 | |
= | 16.09 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Halozyme Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 1.52 | / | 131.7762 | * | 131.7762 | |
= | 1.520 |
Current CPI (Mar. 2024) = 131.7762.
Halozyme Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.149 | 100.560 | 0.195 |
201409 | 0.118 | 100.428 | 0.155 |
201412 | 0.244 | 99.070 | 0.325 |
201503 | 0.149 | 99.621 | 0.197 |
201506 | 0.323 | 100.684 | 0.423 |
201509 | 0.164 | 100.392 | 0.215 |
201512 | 0.407 | 99.792 | 0.537 |
201603 | 0.333 | 100.470 | 0.437 |
201606 | 0.261 | 101.688 | 0.338 |
201609 | 0.249 | 101.861 | 0.322 |
201612 | 0.304 | 101.863 | 0.393 |
201703 | 0.230 | 102.862 | 0.295 |
201706 | 0.252 | 103.349 | 0.321 |
201709 | 0.445 | 104.136 | 0.563 |
201712 | 1.244 | 104.011 | 1.576 |
201803 | 0.216 | 105.290 | 0.270 |
201806 | 0.245 | 106.317 | 0.304 |
201809 | 0.178 | 106.507 | 0.220 |
201812 | 0.418 | 105.998 | 0.520 |
201903 | 0.386 | 107.251 | 0.474 |
201906 | 0.269 | 108.070 | 0.328 |
201909 | 0.316 | 108.329 | 0.384 |
201912 | 0.381 | 108.420 | 0.463 |
202003 | 0.185 | 108.902 | 0.224 |
202006 | 0.400 | 108.767 | 0.485 |
202009 | 0.460 | 109.815 | 0.552 |
202012 | 0.834 | 109.897 | 1.000 |
202103 | 0.599 | 111.754 | 0.706 |
202106 | 0.924 | 114.631 | 1.062 |
202109 | 0.790 | 115.734 | 0.900 |
202112 | 0.707 | 117.630 | 0.792 |
202203 | 0.830 | 121.301 | 0.902 |
202206 | 1.071 | 125.017 | 1.129 |
202209 | 1.499 | 125.227 | 1.577 |
202212 | 1.302 | 125.222 | 1.370 |
202303 | 1.176 | 127.348 | 1.217 |
202306 | 1.655 | 128.729 | 1.694 |
202309 | 1.611 | 129.860 | 1.635 |
202312 | 1.755 | 129.419 | 1.787 |
202403 | 1.520 | 131.776 | 1.520 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Halozyme Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J. Labarre | officer: SVP, Chief Technical Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Helen Torley | director, officer: President and CEO | C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Jeffrey William Henderson | director | 7000 CARDINAL PLACE, DUBLIN OH 43017 |
Nicole Labrosse | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Akiko Moni Miyashita | director | 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501 |
Mark Howard Snyder | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Matsui Connie | director | 3030 CALLAN RD, SAN DIEGO CA 92121 |
Jean-pierre Bizzari | director | 235 LAUREL LN, HAVERFOLD PA 19041 |
Kenneth J Kelley | director | 1331 HILLVIEW DRIVE, MENLO PARK CA 94025 |
Elaine D Sun | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Masaru Matsuda | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: SVP, Chief Commerical Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
From GuruFocus
By PRNewswire • 07-25-2023
By GuruFocus Research • 01-18-2024
By PRNewswire • 01-18-2024
By PRNewswire • 10-30-2023
By PRNewswire • 06-21-2023
By GuruFocus Research • 09-20-2023
By GuruFocus Research • 10-18-2023
By PRNewswire PRNewswire • 05-03-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 06-20-2023